





Drug metabolism

- · · · · · · · · · · · · · · · · · ·
- Important
- Main Text
- Male slides
- female slides
- Extra information
- Doctors notes
- For any future corrections Editing file
- If you didn't understand any part from this lecture Click here



Objectives

- Recognize the importance of biotransformation
- Know the different sites for drug metabolism
- Define the major phase I and phase II metabolic reactions.
- Describe the modulation of liver microsomal enzymes by inducers and inhibitors
- Mention two drugs that are known as enzyme inducers and inhibitors.
- Know the impact of first pass metabolism on drug bioavailability.

Metabolism

Definition: Chemical reactions which occur in the body to change drugs from non polar lipid soluble forms to polar water soluble forms that are easily excreted by the kidney.

Importance:

- Inactivation or termination of drug action (most drugs)
- Detoxification
 Biotransformation is required for protection of body from toxic metabolites
- Activation of prodrug (convert inactive form of drug to active form)*

The patient takes it in the inactive form, it becomes active after the metabolism

Sites:

- Liver (the major site).
- Intestinal Mucosa and Lumen
- Plasma
- Kidney
- Skin
- Lung

Intestinal Mucosa and Lumen

Gut Mucosa

- Mono-Amine Oxidase (MAO).*
- *for drugs with amine groups
 - Gut lumen (bacterial flora)**
 - Glucouronidase
 - **produced by bacteria



Cellular sites of drug metabolism in liver

Mitochondria	 N-acetyl transferase: Introduction of acetyl group (CH₃ COO-) Monoamine oxidase enzyme (MAO): Oxidation of catecholamines as adrenaline
Cytoplasm	E.g. Alcohol dehydrogenase: oxidation of alcohol NAD+ → NADH Alcohol → Aldehyde → Acid Ethanol → Acetaldehyde → Acetic acid CH3CH2OH → CH3CHO → CH3COOH
Microsomes	Microsomal enzyme system = Cytochrome P-450 (Oxidation). There are more than 20 families CYP1, CYP2, CYP3 (In humans: only these 3 isoenzyme families are important) Sub-families are identified as A, B, and C etc. CYP 3A4/5 carry out biotransformation of the largest number (30–50%) of drugs. Expressed in liver and intestine (responsible for first pass metabolism at this site)
Lysosomes	

Types of hepatic metabolic reactions



Oxidation

Oxidation

removal of H

metabolizing

The most

reaction



oxidation Non-microsomal <u>oxidases</u> [contd...]



3) Xanthine oxidase:

• Is required for the oxidation of xanthine

oxidase oxidase

- Hypoxanthine -----> xanthine -----> uric acid
- uric acid accumulation ---> GOUT

Allopurinol: is an inhibitor of xanthine oxidase, and used in the treatment of Gout.

Reduction Reaction:	 Removal of oxygen or addition of hydrogen. May be microsomal or non-microsom al. 	Example: Levodopa HO HO Levodopa (DOPA)	HO HO HO Dopamine Dopamine deficiency will cause <u>Parkinson's disease</u>
	 All are non microsomal 	1- Esterases : hydrolyze drugs that are <u>esters</u>	e.g: Acetylcholine (Ach) (Neurotransmitter)
Hydrolysis Reactions:	 Occurs by addition of water molecules in presence of enzymes as (esterases & amidases) 	$\frac{Q}{R} = \frac{Q}{OR'}$ 2- Amidases: hydrolyze drugs that are <u>amides</u> $\frac{Amide + H2O}{R} = \frac{Acid+Amine}{K}$	$\frac{1}{10000000000000000000000000000000000$



Phase II Conjugation Reactions (example of Phase II Reactions)



Types of conjugation reactions

•	Conjugation reaction	Enzyme required	•
	Glucuronide conjugation	Glucouronyl transferase	
	Acetylation (CH ₃ COO-)	N-acetyl <u>transferase</u>	
	Sulphation (SO ₄)	Sulfo <u>transferase</u>	
	Methylation (CH ₃)	Methyl <u>transferase</u>	•
	Amino acids conjugation	Glycine conjugation	



It is forbidden to give chloramphenicol to children under 2 years

Phase II Metabolic Reactions

All are non microsomal <u>except</u> glucouronidation Glucouronide conjugation is a microsomal process **(the most common of phase II reactions)** Deficiency of glucuronyl transferase enzyme in neonates may result in toxicity with Chloramphenicol (Gray baby syndrome).



Nutrition Malnutrition Decreases metabolism Due to less dietary amino acids (proteins) in the body Age Decreased metabolism in neonates & elderly. older people have a lower metabolism than young people.

Factors affecting metabolism **Diseases** Decreased metabolism in

people with liver diseases & kidney diseases

Concurrent use of drugs Can cause inhibition or induction (in liver microsomal enzyme) Degree of protein binding Protein binding increases, metabolism decreases too. E.g: In blood

Factors affecting metabolism (contd...)

Genetic polymorphism:

Metabolism may vary from population to another due to the existence of different forms of the metabolic enzymes. E.g.metabolism of isoniazid (Anti-TB).

Rapid Acetylator Phenotype	Slow Acetylator Phenotype	
Risk of hepatitis.	Risk of peripheral neuropathy	
Results into excess metabolites produced	Results in accumulation of isoniazid	
Increased isoniazid metabolism	Decrease in isoniazid metabolism	

helpful video	Enzyme Induction	Enzyme Inhibition
Liver microsomal enzymes:	Drugs that increase activities of liver microsomal enzymes & increase the metabolism of drug itself and other drugs taken with the inducer at the same time.	Drugs that decrease activities of liver microsomal enzymes & decrease the metabolism of the drug itself and other drugs taken concurrently.
examples:	 Alcohol Cigarette smoking Phenobarbitone (hypnotic) Phenytoin (antiepileptic) Rifampicin (Anti TB) 	 Grape fruits Cimetidine Erythromycin (antibiotic) Ketoconazole (antifungal)
Metabolism & excretion of drug itself & co-administered drugs:	Increase	Decrease (Delay)
Action of the drug itself & co-administered drugs:	Decrease	increase (Prolong)

[CONTD]	Enzyme Induction	Enzyme inhibition
Drug interactions:	decrease in action of one drug by administration of another drug e.g. <u>oral contraceptives</u> & phenytoin (inducer). Failure of oral contraceptive may lead to pregnancy if combined with phenytoin. ملاحظة (team 439): الـphenytoin): المراة تأخذ الدوائين مع بعض ، إذن دواء منع تكسر دواء منع الحمل ، فإذا كانت المرأة تأخذ الدوائين مع بعض ، إذن دواء منع	e.g. <u>warfarin</u> & erythromycin (inhibitor). Inhibition of warfarin metabolism may lead to increase in its anticoagulant effect (risk of bleeding). ملاحظة (team 439): لا erythromycin التي تكسر دواء ال warfarin الذي المناط
May occur:	Tolerance: decrease in the pharmacological action of the drug by continuous or repeated administration .	و يسبب بريك.



metabolites are usually inactive.



1.The addition of glucuronic acid to a drug?					
A. Decreases its water solubility.	B. Usually the drug metabolite is inactive.	C. Is an example of a Phase I reaction.	D. Involves cytochrome P450 enzymes.		
2.Which of the follo	wing describes the	first-pass effect?			
A.Drug given orally is metabolized by the liver before entering the circulation.	B. Absorption of a drug through the duodenum.	C.Drug given IV accumulates quickly in the central nervous system (CNS).	D. Inactivation of a drug as a result of the gastric acids.		
3.Which one of these sites is not responsible for drug metabolism?					
A.Skin.	B.Kidney.	C.Spleen.	D.Intestinal lumen.		

Answers





4.Hydrolysis reaction	ons are?					
A.non microsomal.	B.none.	C.both.	D.microsomal.	4	Ansv	vers
					4	А
5.How many familie	es are in the microso	mal enzyme system '	?		5	В
A.3	B.20	C.15	D.10		6	D
6.Which of these drugs used for gout treatment ?					7	А
A.rifampicin	B.erythromycin	C.moclobemide	D.allopurinol			•
7.Which of these drugs used as antidepressant ?						
A.moclobemide	B.phenobarbitone	C.allopurinol	D.ketoconazole		•	



A) List the cellular sites of drug metabolism?

B) Where does non-microsomal oxidation occur?

C) Name a monoamine oxidase inhibitor?

Mitochondria, cytoplasm, microsomes, lysosomes

B) Mitochondria and cytoplasm

C) Moclobemide



Team leaders

Lujain Alkhalaf – Salman Alotaibi

Female team members:

- Alanoud Albawardi
- Shaimaa Alqaoud
- Nada Alsaif
- Raneem Alanazi
- Ftoon Alenazi
- Areej Altamimi
- Sarah Alotaibi
- Rand Alshaya
 - Rand Aldajani

Male team members:

- Anas Alharbi
- Abdulrahman Alghamdi
- Abdullah Alotaibi
- Abdulaziz Aqusaiyer
- Bader Alshahrani
- Saad Alghadir
- Abdullah Alghamdi
- Mohammed Alsaqabi
- Abdulrahman Badghaish

Contact us on:

pharma411m@gmail.com